A study to test a new immunotherapy, ABX-001, alone and in combination with the marketed drug, pembrolizumab, for the treatment of tumors previously treated with other therapies.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512403-39-01

Acronym

ABX-001-01

Enrollment

Registered

2025-09-22

Start date

2025-10-03

Completion date

Unknown

Last updated

2026-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Solid Tumors Who Are Beyond Standard of Care

None listed

Sex/Gender

All

Age

18 Years to No maximum

Germany, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026